Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease
Recruiting
Phase 4
Interventional Study
Crohn Disease (CD)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 75 (estimated)
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients with CD
* ≥ 18 to ≤ 75 years-old
* Symptomatic CD according to PRO-2 (stool \> 3 or abdominal pain score \> 1)
* Transmural inflammation on baseline MRI (C-score \> 0.5 in at least one segment)
Exclusion Criteria:
* Prior exposure to anti-p19 biological therapy
* Ex…
Contacts